Antibody-Drug Conjugates (ADCs)

  1. Home
  2. »
  3. Antibody-Drug Conjugates (ADCs)

Engineered to deliver highly targeted treatments, Antibody-Drug Conjugates (ADCs) are at the forefront of innovative cancer therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs.

Precision-Driven Cancer Treatment

ADCs effectively targets and eradicates cancer cells while sparing healthy tissues, utilizing three core components:

Monoclonal Antibodies

Target cancer cell-specific antigens with exceptional precision.

Cytotoxic Payloads

Deliver potent chemotherapy directly to cancer cells.

Chemical Linkers

Ensure stability during circulation and controlled release at the tumor site.

Anthem’s Role in ADCs

Continued advancements in linker technology, payload optimization and mAb engineering are driving the development of next-generation ADCs with improved precision, stability and efficacy.

At Anthem, we are committed to accelerating ADC research and development, leveraging our expertise in process chemistry and advanced manufacturing techniques.

  • Enhanced Efficacy
  • Reduced Side Effects
  • Broad Applicability